Physician profile
Yi Huang
NPI 1063755395
$799.18
in general payments reported to CMS, 2019-2025
15 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $15.48 · 2021: $11.03 · 2022: $17.33 · 2024: $119 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $206.37 | 2024-2025 | Hemoblast Bellows |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Stryker Corporation | $116.49 | 2025 | Molli |
| Integra Lifesciences Corporation | $61.51 | 2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Acera Surgical, INC. | $50.84 | 2024-2025 | Restrata Wound Matrix |
| Gilead Sciences, INC. | $38.36 | 2022-2024 | |
| Conmed Corporation | $34.09 | 2025 | Airseal |
| Puma Biotechnology, INC. | $31.21 | 2019-2020 | |
| Kerecis Limited | $30.75 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Smith+Nephew, INC. | $25.11 | 2025 | Renasys Touch |
| Takeda Pharmaceuticals U.S.A., INC. | $17.67 | 2025 | Fruzaqla |
| Tesaro, INC. | $17.65 | 2019 | |
| Ambu INC. | $17.13 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $15.98 | 2025 | Exparel |
| Myriad Genetic Laboratories, INC. | $11.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.